Drugs / Moexipril
Moexipril
also known as
Univasc · CI 925 · Moexipril HCl · MOEXIPRIL HYDROCHLORIDE · Moexipril hydrochloride component of uniretic · Perdix · RS-10085 · RS-10085-197 · +2 more
Small molecule targets ACE via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | UNIVASC | — | 1995-04-19 | fda.gov ↗ |
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 2 met primary | ||||||
| Phase 1 | NCT00834067 | Oct → Nov 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00835042 | Oct → Nov 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00992862 | — | — | Paddock Laboratories, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00588302 | Jun 2003 → Jun 2007 | primary biliary cholangitis | Mayo Clinic | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01669434 | Jun 2015 → Nov 2016 | — | University of Nebraska | Completed | Met primary |
| Phase not applicable1 trial · 1 missed | ||||||
| — | NCT01867047 | Jun 2013 → Jun 2016 | hypotensive disorder | Duke University | Terminated | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT07547878 Comparator | Apr 2026 → Mar 2029 expected | chronic kidney disease, type 2 diabetes mellitus | Baylor Research Institute | Not yet recruiting | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2007-03-11 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Receives First U.S. Approval For Generic UNIRETIC® Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDAfor Moexipril HCland HydrochlorothiazideTablets, 7.5 mg/12.5 mg, 15 mg/12.5 mg and 15 mg/25 mg. |
| 2003-05-08 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval of Moexipril HCl Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has approved the company's ANDA for Moexipril HCl Tablets, 7.5 mg and 15 mg. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2007-03-11 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Receives First U.S. Approval For Generic UNIRETIC® Tablets tevapharm.com ↗ |
| 2004-09-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Enters Into Agreement With Schwarz Pharma to Suspend Sales of Moexipril Pending Outcome of Litigation tevapharm.com ↗ |
| 2004-01-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Comments On The Court Of Appeals Decision Regarding Moexipril tevapharm.com ↗ |
| 2003-05-08 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Moexipril HCl Tablets tevapharm.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | moexipril | “Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗ |
| Known as | CI 925 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1165 ↗ |
| Known as | Moexipril HCl | “Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.” NCT00992862 ↗ |
| Known as | MOEXIPRIL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1165 ↗ |
| Known as | Moexipril hydrochloride component of uniretic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1165 ↗ |
| Known as | Perdix | ChEMBL registry synonym — accepted as the source's own label CHEMBL1165 ↗ |
| Known as | RS-10085 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1165 ↗ |
| Known as | RS-10085-197 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1165 ↗ |
| Known as | SPM 925 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1165 ↗ |
| Known as | Uniretic | ChEMBL registry synonym — accepted as the source's own label CHEMBL1165 ↗ |
| Known as | Univasc | “Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗ |
| Action | Inhibit | “moexipril, an angiotensin-converting enzyme (ACE) inhibitor” NCT00588302 ↗1“Angiotensin-converting enzyme inhibitor” CHEMBL1165 ↗ |
| Modality | Small molecule | — CHEMBL1165 ↗ |
| Route | Oral | “Patients took moexipril orally in the morning and 1 hour prior to food intake.” NCT00588302 ↗ |
| Target | ACE | “Angiotensin-converting enzyme inhibitor” CHEMBL1165 ↗ |